Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes

Download All
Gain multidisciplinary expert insights on the latest approved AML therapies to improve the care of patients with newly diagnosed or relapsed/refractory disease with these downloadable slides and on-demand Webcast of a CCO/NCCN Webinar.
Amir T. Fathi, MD
Daniel Pollyea, MD, MS
Eunice S. Wang, MD

Downloadable Slidesets

Download these expert-selected slides on treating patients with ND AML without targetable biomarkers

Daniel Pollyea, MD, MS Released: June 17, 2021

Download these expert-selected slides on treating patients with AML with targetable biomarkers.

Amir T. Fathi, MD Released: June 17, 2021

Download these expert-selected slides on novel investigational treatments and MRD testing in AML

Eunice S. Wang, MD Released: June 17, 2021

Download this short slideset on current optimal therapy for patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML)

Amir T. Fathi, MD Daniel Pollyea, MD, MS Eunice S. Wang, MD Released: June 23, 2021
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Astellas Pharma US, Inc.
Pfizer, Inc.
Servier Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings